Skip to main content

Advertisement

Table 5 Multivariate analysis of ABCB1 promoter methylation and its association with the overall survival of GBM patients

From: Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

Variable Haz. ratio p-value [95% Conf. Interval]
Sex    
male 1.457 0.276 0.740 2.866
(ref. female) 1.130 0.793 0.454 2.813
4.222 0.043 1.045 17.060
Age     
50- < 60 years 1.793 0.282 0.619 5.191
(ref. <50 years) 1.500 0.490 0.474 4.742
5.358 0.234 0.338 84.863
Age     
60- < 70 years 2.474 0.066 0.942 6.499
(ref. <50 years) 2.235 0.140 0.768 6.507
3.596 0.290 0.336 38.441
Age     
≥70 years 6.069 0.001 2.107 17.479
(ref. <50 years) 9.872 0.000 2.786 34.988
5.112 0.167 0.505 51.721
Mean methylation level (continuous)     
0.995 0.461 0.981 1.009
1.002 0.864 0.984 1.020
  0.973 0.032 0.950 0.998
  1. Continuous multivariate Cox model regression analysis of ABCB1 promoter methylation and its association with the overall survival (OS) of the analyzed patients with glioblastoma multiforme, adjusted for potential risk factors including sex and age at diagnosis and stratified on the variable therapy. Normal typed data: the entire glioblastoma cohort; Italic data: Temozolomide treated glioblastoma patients; Bold face data: Glioblastoma patients without temozolomide treatment (Haz. Ratio, Hazard Ratio; Conf. Interval, Confidence Interval).